文献速递免疫规划卫生政策与健康促进

澳大利亚ChAdOx1-S疫苗接种后血栓伴血小板减少综合征12个月临床、心理与生活质量结局

Clinical, psychological and quality of life outcomes up to 12-months following thrombosis with thrombocytopenia syndrome after ChAdOx1-S (AZD1222) vaccination in Australia.
PubMed 文献 · Vaccine · 2026-03-23

该全国性队列研究随访2021年澳大利亚确诊的TTS幸存者至出院后12个月,92例完成随访。12个月时61%有持续症状,其心理困扰显著高于无症状者,生活质量各维度均差于澳大利亚人群常模;复发血栓和出血并发症少见,多数后续接种新冠疫苗无严重不良事件。

要点

  • TTS出院后12个月61%报告持续症状,心理困扰和生活质量显著受损。
  • 复发血栓和出血并发症少见,多数患者后续接种新冠疫苗无严重不良事件。
  • 建议以生物心理社会模式对TTS进行结构化长期随访。

核心结论

  • TTS出院后12个月持续症状常见,伴随功能受限、心理困扰和生活质量显著降低。
  • 复发血栓和出血并发症不常见,后续接种新冠疫苗未报告严重不良事件。

研究设计与样本

  • 全国性队列研究,纳入2021年3月23日至12月31日澳大利亚确诊TTS的成人,随访至出院后12个月。
  • 161例TTS幸存者中92例(57%)完成12个月随访。

主要发现

  • 48%在12个月时仍接受抗凝治疗。
  • 报告2例临床相关非大出血和3例新发血栓事件。
  • 93%接受了后续新冠疫苗,未报告免疫接种后严重不良事件。
  • 61%在出院后12个月报告持续症状,其抑郁、焦虑和创伤后应激等心理困扰显著高于无症状者。
  • 所有躯体和心理领域的生活质量评分均显著低于澳大利亚人群常模,6至12个月间躯体和社会功能仅有 modest 改善。

临床怎么用

  • 对TTS幸存者进行结构化长期随访,采用生物心理社会模式整合医学、心理和功能管理。
  • 通过疫苗伤害赔偿计划为TTS患者提供支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thrombosis with thrombocytopenia syndrome (TTS) associated with viral vector COVID-19 vaccines, including ChAdOx1-S (AstraZeneca AZD1222) vaccine, can result in significant morbidity and mortality. However, evidence on long-term clinical and psychosocial outcomes is limited. We report on the 12-month clinical, psychological and health-related quality of life (HRQoL) outcomes of TTS in Australia. METHODS: In this national cohort study, adults diagnosed with TTS in Australia between 23 March and 31 December 2021 were followed up to 12 months post-discharge. Data were collected on clinical progression, disability, revaccination outcomes, psychological functioning and HRQoL. Psychological functioning and HRQoL were compared between participants with and without persistent clinical symptoms at 12 months. FINDINGS: Of the 161 TTS surviving cases, 92 (57%) completed 12-month follow-up, with 48% remaining on anticoagulation. Two clinically relevant non-major bleeds, and three new thrombotic events were reported. Most cases (93%) received a subsequent COVID-19 vaccine, with no serious adverse events following immunisation. At 12 months post-discharge, 61% reported persistent symptoms, and had significantly higher levels of psychological distress, including depression, anxiety, and post-traumatic stress, compared to asymptomatic cases. HRQoL scores were significantly poorer than Australian population norms across all physical and mental domains, with only modest improvements in physical and social functioning observed between 6 and 12 months. CONCLUSION: Recurrent thrombosis and haemorrhagic complications were uncommon; however persistent symptoms at 12-months post-discharge from TTS were frequent and accompanied by substantial functional limitations, psychological distress, and significantly reduced HRQoL. These findings highlight the importance of structured long-term follow-up of TTS, a serious adverse event following immunisation, using a biopsychosocial model of care integrating medical, psychological and functional management and support through a vaccine injury compensation scheme.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Deng L, Barton B, Choi P, et al. Clinical, psychological and quality of life outcomes up to 12-months following thrombosis with thrombocytopenia syndrome after ChAdOx1-S (AZD1222) vaccination in Australia. Vaccine. 2026. PMID: 41875690. doi:10.1016/j.vaccine.2026.128501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。